Clene to Present at the 37TH Annual Roth Conference
Clene Inc. (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments, has announced its participation in the 37th Annual Roth Conference. The company, which focuses on developing treatments for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), will engage in a virtual fireside chat on March 18, 2025, at 9:20 am PST.
The presentation will be accessible through a webcast on the company's website's 'Events' section. Additionally, Clene's management team will be available for one-on-one investor meetings, which can be arranged through Roth representatives.
Clene Inc. (Nasdaq: CLNN), un'azienda biofarmaceutica in fase clinica avanzata specializzata nel trattamento delle malattie neurodegenerative, ha annunciato la sua partecipazione alla 37ª Conferenza Annuale Roth. L'azienda, che si concentra sullo sviluppo di trattamenti per la sclerosi laterale amiotrofica (SLA) e la sclerosi multipla (SM), parteciperà a una chiacchierata virtuale il 18 marzo 2025, alle 9:20 PST.
La presentazione sarà accessibile tramite un webcast nella sezione 'Eventi' del sito web dell'azienda. Inoltre, il team di gestione di Clene sarà disponibile per incontri individuali con gli investitori, che possono essere organizzati tramite i rappresentanti di Roth.
Clene Inc. (Nasdaq: CLNN), una empresa biofarmacéutica en etapa clínica avanzada especializada en tratamientos para enfermedades neurodegenerativas, ha anunciado su participación en la 37ª Conferencia Anual Roth. La empresa, que se centra en el desarrollo de tratamientos para la esclerosis lateral amiotrófica (ELA) y la esclerosis múltiple (EM), participará en una charla virtual el 18 de marzo de 2025, a las 9:20 am PST.
La presentación estará disponible a través de una transmisión en vivo en la sección 'Eventos' del sitio web de la empresa. Además, el equipo de gestión de Clene estará disponible para reuniones individuales con inversores, que se pueden organizar a través de los representantes de Roth.
Clene Inc. (Nasdaq: CLNN)은 신경퇴행성 질환 치료를 전문으로 하는 후기 임상 단계의 생명공학 회사로, 제37회 연례 로스 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 근위축성 측삭경화증 (ALS) 및 다발성 경화증 (MS) 치료 개발에 집중하고 있으며, 2025년 3월 18일 오전 9시 20분 PST에 가상 대담에 참여할 예정입니다.
프레젠테이션은 회사 웹사이트의 '이벤트' 섹션을 통해 웹캐스트로 접근할 수 있습니다. 또한, Clene의 경영진은 Roth 대표를 통해 조정할 수 있는 일대일 투자자 회의에 참석할 수 있습니다.
Clene Inc. (Nasdaq: CLNN), une entreprise bio-pharmaceutique en phase clinique avancée spécialisée dans le traitement des maladies neurodégénératives, a annoncé sa participation à la 37ème Conférence Annuelle Roth. L'entreprise, qui se concentre sur le développement de traitements pour la sclérose latérale amyotrophique (SLA) et la sclérose en plaques (SEP), participera à une discussion virtuelle le 18 mars 2025 à 9h20 PST.
La présentation sera accessible via un webinaire dans la section 'Événements' du site web de l'entreprise. De plus, l'équipe de direction de Clene sera disponible pour des réunions individuelles avec les investisseurs, qui peuvent être organisées par l'intermédiaire des représentants de Roth.
Clene Inc. (Nasdaq: CLNN), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Behandlung neurodegenerativer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 37. jährlichen Roth-Konferenz angekündigt. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für amyotrophe Lateralsklerose (ALS) und multiple Sklerose (MS) konzentriert, wird am 18. März 2025 um 9:20 Uhr PST an einem virtuellen Gespräch teilnehmen.
Die Präsentation wird über einen Webcast im Bereich 'Veranstaltungen' der Unternehmenswebsite zugänglich sein. Darüber hinaus wird das Management-Team von Clene für persönliche Investorenmeetings zur Verfügung stehen, die über Roth-Vertreter arrangiert werden können.
- None.
- None.
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate in a fireside chat at the 37th Annual Roth Conference and host 1x1 investor meetings.
Date: March 18, 2025
Time of Presentation: 9:20 am PST
Format: Virtual Fireside Chat
1x1 Meetings: Please contact your Roth representative.
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
FAQ
When and where is Clene (CLNN) presenting at the 37th Annual Roth Conference?
How can investors access Clene's (CLNN) Roth Conference presentation?
What therapeutic areas does Clene (CLNN) focus on in their drug development?
How can investors schedule 1-on-1 meetings with Clene (CLNN) management at the Roth Conference?
